Alicia Levey

Alicia Levey joined Pionyr in July 2019 and leads business development, business operations, portfolio strategy, and program management in addition to managing intellectual property and legal functions. Prior to Pionyr, Dr. Levey served as the Chief Business Officer of Tempest Therapeutics and was a key contributor to establishing the company outside of Inception Sciences and raising $70M in venture funding. Leading up to the spin-out of Tempest, she was VP of Business Development at Inception Sciences, a small molecule drug discovery company formed in collaboration with Versant Ventures, a global venture capital firm focused primarily on early stage investing and biotechnology company creation. Dr. Levey served as a member of the Versant Ventures Investment Team for over 8 years, most recently as an Operating Principal. While at Versant, she was a key contributor to multiple Series A investments (Novira, Audentes, Therachon among others) and business development efforts for portfolio companies. Dr. Levey worked as a Consultant, and later a Project Leader in The Boston Consulting Group. While at BCG, she focused primarily on biopharma and global health. Dr. Levey has authored several peer reviewed scientific publications and her inventions are covered in two United States Patents. Dr. Levey earned a Ph.D. in Cancer Biology from the Stanford University School of Medicine.